Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome

Overview of attention for article published in New England Journal of Medicine, November 2018

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (99th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 76 news outlets
blogs: 7 blogs
policy: 3 policy sources
twitter: 445 X users
patent: 15 patents
facebook: 18 Facebook pages
wikipedia: 4 Wikipedia pages

googleplus: 2 Google+ users
reddit: 11 Redditors
f1000: 1 research highlight platform
video: 3 YouTube creators
guideline: 26 clinical guideline sources
podcasts: 5 podcasts

Readers on

mendeley: 1876 Mendeley

So far, Altmetric has seen 4 citations on 4 Wikipedia pages.

French

Alirocumab

Cited by user ~2026-20929-30 on 06 Apr 2026

L'alirocumab est un anticorps monoclonal humain de la classe des anti-PCSK9 utilisé dans l'hypercholestérolémie familiale et en cours de test dans les autres types d'hyper…

Indonesian

Alirokumab

Cited by user Muhammad Anas Sidik on 29 Nov 2024

Alirokumab (Nama Generik Internasional) adalah obat yang digunakan sebagai pengobatan lini kedua untuk kolesterol tinggi bagi orang dewasa yang kolesterolnya tidak…

English

Alirocumab

Cited by user Whywhenwhohow on 02 Apr 2021

Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not controlled by…

German

Alirocumab

Cited by user Mabschaaf on 06 Jul 2019

This page shows the most recent Wikipedia articles that mention this research output. Click here to find out how to access more activity.